Jéssica Cristina Bilizario Noguerol Andrade
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jéssica Cristina Bilizario Noguerol Andrade has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Fernando de Sá Del Fiol
Doctoral Program, Pharmaceutical Sciences, University of Sorocaba, Sorocaba 18023-000, SP, Brazil
3 shared publications - Leandro Aparecido de Souza
Doctoral Program, Pharmaceutical Sciences, University of Sorocaba, Sorocaba 18023-000, SP, Brazil
2 shared publications - Beatriz Birelli Do Nascimento
Postgraduate Program in Pharmaceutical Sciences - University of Sorocaba, Sorocaba, Brazil
1 shared publication - Beatriz Souza Santos
Doctoral Program, Pharmaceutical Sciences, University of Sorocaba, Sorocaba 18023-000, SP, Brazil
1 shared publication - Bianca Gianola Belline Silva
Programa de Pós-Graduação em Ciências Farmacêuticas, Universidade de Sorocaba (UNISO), Sorocaba 18273-683, SP, Brazil
1 shared publication
Latest Publications
- Open Access
- 17 May 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (5) , 500
Microbiological Profile and Antimicrobial Resistance Patterns in an Intensive Care Unit: Emphasis on ESKAPE Pathogens
Background/Objectives: Antimicrobial resistance (AMR) is a major global public health threat, particularly in intensive care units (ICUs), where critically ill patients are exposed to high antimicrobial pressure. ESKAPE pathogens play a central role in healthcare-associated infections and are frequently associated with multidrug resistance. This study aimed to evaluate the microbiological profiles and antimicrobial resistance patterns of bacterial isolates from an adult ICU in a tertiary hospital in Brazil. Methods: A retrospective, observational, cross-sectional study was conducted using microbiological culture data from patients admitted during 2024 to the adult intensive care unit of a tertiary hospital in Brazil. Bacterial isolates from clinical specimens were included, and antimicrobial susceptibility testing was performed according to routine laboratory procedures. Descriptive statistics were used to summarize microorganism frequency and antimicrobial resistance rates. Results: A total of 1869 isolates were analyzed, with predominance of Gram-negative bacteria. The most frequent pathogens were Klebsiella pneumoniae (287/1869; 15.33%), Staphylococcus haemolyticus (164/1869; 8.76%), Enterococcus faecalis (144/1869; 7.69%), and Acinetobacter baumannii (135/1869; 7.21%). A high proportion of isolates belonged to the ESKAPE group. Gram-negative bacteria, particularly Klebsiella pneumoniae and Acinetobacter baumannii, showed high resistance to β-lactams, cephalosporins, carbapenems, and quinolones. Among Gram-positive organisms, resistance was high for macrolides, oxacillin, and clindamycin, while glycopeptides and linezolid remained effective. Conclusions: These findings highlight the importance of continuous microbiological surveillance and robust antimicrobial stewardship strategies. The present study adds novel local epidemiological evidence from a Brazilian ICU by integrating species-level distribution, antimicrobial-specific resistance, and resistance patterns by pharmacological class, with particular emphasis on ESKAPE pathogens.
- 17 May 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (5) , 500
Open AccessMicrobiological Profile and Antimicrobial Resistance Patterns in an Intensive Care Unit: Emphasis on ESKAPE Pathogens
Background/Objectives: Antimicrobial resistance (AMR) is a major global public health threat, particularly in intensive care units (ICUs), where critically ill patients are exposed to high antimicrobial pressure. ESKAPE pathogens play a central role in healthcare-associated infections and are frequently associated with multidrug resistance. This study aimed to evaluate the microbiological profiles and antimicrobial resistance patterns of bacterial isolates from an adult ICU in a tertiary hospital in Brazil. Methods: A retrospective, observational, cross-sectional study was conducted using microbiological culture data from patients admitted during 2024 to the adult intensive care unit of a tertiary hospital in Brazil. Bacterial isolates from clinical specimens were included, and antimicrobial susceptibility testing was performed according to routine laboratory procedures. Descriptive statistics were used to summarize microorganism frequency and antimicrobial resistance rates. Results: A total of 1869 isolates were analyzed, with predominance of Gram-negative bacteria. The most frequent pathogens were Klebsiella pneumoniae (287/1869; 15.33%), Staphylococcus haemolyticus (164/1869; 8.76%), Enterococcus faecalis (144/1869; 7.69%), and Acinetobacter baumannii (135/1869; 7.21%). A high proportion of isolates belonged to the ESKAPE group. Gram-negative bacteria, particularly Klebsiella pneumoniae and Acinetobacter baumannii, showed high resistance to β-lactams, cephalosporins, carbapenems, and quinolones. Among Gram-positive organisms, resistance was high for macrolides, oxacillin, and clindamycin, while glycopeptides and linezolid remained effective. Conclusions: These findings highlight the importance of continuous microbiological surveillance and robust antimicrobial stewardship strategies. The present study adds novel local epidemiological evidence from a Brazilian ICU by integrating species-level distribution, antimicrobial-specific resistance, and resistance patterns by pharmacological class, with particular emphasis on ESKAPE pathogens.
- Open Access
- 3 March 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (3) , 264
Impact of an Antimicrobial Stewardship Program on Antibiotic Consumption, Bacterial Susceptibility, and Costs in a High-Complexity Public Hospital
Background/Objectives: Antimicrobial resistance (AMR) is a major global public health threat, particularly in hospitals. Antimicrobial Stewardship Programs (ASPs) aim to optimize prescribing, reduce unnecessary exposure to broad-spectrum agents, and mitigate resistance. This study evaluated the clinical, ecological, and economic impact of an ASP implemented in January 2021 in a high-complexity hospital in Brazil, focusing on antimicrobial consumption, temporal trends in bacterial susceptibility, and direct antimicrobial-related costs. Methods: A quasi-experimental pre–post study using an interrupted time-series design was conducted in the adult intensive care unit from January 2019 to December 2023. Antimicrobial consumption was measured as Defined Daily Doses per 1000 patient-days (DDD/1000-PD) for ceftriaxone, meropenem, piperacillin–tazobactam, vancomycin, and polymyxin B. Temporal trends were assessed using Joinpoint regression, and pre- and post-intervention periods were compared using Student’s or Mann–Whitney tests. Susceptibility data were interpreted according to BrCAST standards. Results: Significant and sustained reductions were observed for all agents except polymyxin B. Susceptibility improved or stabilized among key Gram-negative pathogens, with a significant increase in aggregated Gram-negative susceptibility after 2021, while intrinsically resistant organisms showed limited change. Annual antimicrobial costs decreased by approximately USD 174,000. Conclusions: The ASP was associated with reduced broad-spectrum antimicrobial use, favorable ecological trends, and substantial cost savings.
- 3 March 2026
- Published by MDPI AG in Antibiotics
- Vol. 15 (3) , 264
Open AccessImpact of an Antimicrobial Stewardship Program on Antibiotic Consumption, Bacterial Susceptibility, and Costs in a High-Complexity Public Hospital
Background/Objectives: Antimicrobial resistance (AMR) is a major global public health threat, particularly in hospitals. Antimicrobial Stewardship Programs (ASPs) aim to optimize prescribing, reduce unnecessary exposure to broad-spectrum agents, and mitigate resistance. This study evaluated the clinical, ecological, and economic impact of an ASP implemented in January 2021 in a high-complexity hospital in Brazil, focusing on antimicrobial consumption, temporal trends in bacterial susceptibility, and direct antimicrobial-related costs. Methods: A quasi-experimental pre–post study using an interrupted time-series design was conducted in the adult intensive care unit from January 2019 to December 2023. Antimicrobial consumption was measured as Defined Daily Doses per 1000 patient-days (DDD/1000-PD) for ceftriaxone, meropenem, piperacillin–tazobactam, vancomycin, and polymyxin B. Temporal trends were assessed using Joinpoint regression, and pre- and post-intervention periods were compared using Student’s or Mann–Whitney tests. Susceptibility data were interpreted according to BrCAST standards. Results: Significant and sustained reductions were observed for all agents except polymyxin B. Susceptibility improved or stabilized among key Gram-negative pathogens, with a significant increase in aggregated Gram-negative susceptibility after 2021, while intrinsically resistant organisms showed limited change. Annual antimicrobial costs decreased by approximately USD 174,000. Conclusions: The ASP was associated with reduced broad-spectrum antimicrobial use, favorable ecological trends, and substantial cost savings.
- Open Access
- 1 January 2026
- Published by Wiley in International Journal of Microbiology
- Vol. 2026 (1)
From Widespread Use to Loss of Effectiveness: The Consequences of Inappropriate Azithromycin Prescriptions During the COVID‐19 Pandemic—A Systematic Review and Meta‐Analysis
Objectives: We are aimed at evaluating whether the widespread use of azithromycin during the COVID‐19 pandemic led to a significant increase in bacterial resistance compared with the prepandemic period and estimating the magnitude of this effect through a systematic review and meta‐analysis. Methods: This systematic review followed the PRISMA 2020 guidelines and Cochrane Handbook (Page,2021). Observational studies published between 2015 and 2025 reporting azithromycin resistance before and after the COVID‐19 pandemic were identified. Odds ratios (ORs) were pooled using a random‐effects model. Methodological quality was assessed using the Newcastle–Ottawa scale. Results: Eight studies met the eligibility criteria and were included in the quantitative synthesis. The meta‐analysis demonstrated a significant increase in azithromycin resistance in the postpandemic period, with a pooled OR of 2.71 (95% CI: 2.04–3.59). Substantial heterogeneity was observed ( I 2 = 73.5 % ), justifying the use of a random‐effects model. Conclusions: The findings provide robust evidence that the excessive and largely empirical use of azithromycin during the COVID‐19 pandemic contributed to a global rise in bacterial resistance. Strengthening antimicrobial stewardship policies is essential to preserve the clinical effectiveness of macrolides during future public health emergencies.
- 1 January 2026
- Published by Wiley in International Journal of Microbiology
- Vol. 2026 (1)
Open AccessFrom Widespread Use to Loss of Effectiveness: The Consequences of Inappropriate Azithromycin Prescriptions During the COVID‐19 Pandemic—A Systematic Review and Meta‐Analysis
Objectives: We are aimed at evaluating whether the widespread use of azithromycin during the COVID‐19 pandemic led to a significant increase in bacterial resistance compared with the prepandemic period and estimating the magnitude of this effect through a systematic review and meta‐analysis. Methods: This systematic review followed the PRISMA 2020 guidelines and Cochrane Handbook (Page,2021). Observational studies published between 2015 and 2025 reporting azithromycin resistance before and after the COVID‐19 pandemic were identified. Odds ratios (ORs) were pooled using a random‐effects model. Methodological quality was assessed using the Newcastle–Ottawa scale. Results: Eight studies met the eligibility criteria and were included in the quantitative synthesis. The meta‐analysis demonstrated a significant increase in azithromycin resistance in the postpandemic period, with a pooled OR of 2.71 (95% CI: 2.04–3.59). Substantial heterogeneity was observed ( I 2 = 73.5 % ), justifying the use of a random‐effects model. Conclusions: The findings provide robust evidence that the excessive and largely empirical use of azithromycin during the COVID‐19 pandemic contributed to a global rise in bacterial resistance. Strengthening antimicrobial stewardship policies is essential to preserve the clinical effectiveness of macrolides during future public health emergencies.